Acrivon Therapeutics, Inc. (ACRV)
↓ Download CSVKey ratios (FY2025)
-69.2%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Income | -$84.11M | -$89.20M | -$67.10M | -$32.66M | -$16.18M | — |
| Net Income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | -$16.24M | — |
| EPS (Diluted) | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 | — |
| Total Assets | $129.72M | $196.59M | $138.26M | $181.23M | $106.59M | — |
| Total Liabilities | $17.20M | $19.80M | $17.07M | $10.75M | $7.88M | — |
| Shareholders' Equity | $112.52M | $176.79M | $121.19M | $170.47M | -$23.81M | -$8.41M |
| Cash & Equivalents | $41.50M | $39.82M | $36.02M | $29.52M | $99.60M | — |
| Operating Cash Flow | -$63.66M | -$65.67M | -$42.64M | -$30.12M | -$13.98M | — |
| Capital Expenditures | $1.67M | $2.77M | $1.29M | $2.17M | $238.0K | — |
| Shares Outstanding | 31.65M | 31.23M | 22.52M | 21.92M | 1.77M | — |